Amplify Weight Loss Drug & Treatment ETF (THNR)
ARCA ARCA Primary Summary
THNR Chart
Inside THNR: A Leaner Approach to Weight Loss Investing
Demand for GLP-1 weight loss drugs has reshaped the healthcare industry. And ETFs such as the Amplify Weight Loss Drug & Treatment ETF (THNR) give investors a way to access this growing market.
Weight Loss ETF THNR Reweights Its Index: What's Up & Down
Weight loss pills and treatments have exploded in popularity since GLP-1 drugs hit the market. From Ozempic to Wegovy, those pills have changed the lives of countless people around the world.
Weight Loss Drug ETF (THNR) Hits New 52-Week High
Amplify Weight Loss Drug & Treatment ETF THNR is probably on the radar for investors seeking momentum. The fund just hit a 52-week high and moved up 51.9% from its 52-week low price of $18.56/share.
Amplify Weight Loss Drug & Treatment ETF (THNR) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Amplify Weight Loss Drug & Treatment ETF ever had a stock split?
Amplify Weight Loss Drug & Treatment ETF Profile
| ARCA Exchange | US Country |
Overview
The fund is dedicated to investing a substantial portion of its assets, specifically at least 80%, in securities that are integral to the index it follows. This index consists of global companies engaged in the manufacturing of GLP-1 agonist pharmaceuticals or in supporting this sector. GLP-1 agonists are a class of medications known for their ability to lower blood sugar levels, reduce appetite, and promote a feeling of fullness, leading potentially to weight loss. Operating with a focus on a specific segment of the pharmaceutical industry, the fund is characterized by its non-diversified status, meaning it may invest more heavily in fewer securities, which can both increase the potential for higher returns and pose a higher risk of volatility.
Products and Services
- GLP-1 Agonist Pharmaceuticals
This product category includes medications developed to mimic the action of the GLP-1 hormone, which is naturally present in the body. These medications work by stimulating insulin release in response to high blood glucose levels, inhibiting glucagon release, and slowing gastric emptying. By doing so, they effectively lower blood sugar levels. Additionally, they help control appetite and promote a sense of fullness, which can assist in weight management. The fund invests in companies that either directly manufacture these pharmaceuticals or play a significant role in their development and distribution within the global market.
- Investment in Enabling Companies
Aside from direct investments in manufacturers of GLP-1 agonist pharmaceuticals, the fund also invests in companies that enable this sector. These enablers could include firms involved in the research and development of new GLP-1 compounds, companies providing specialty pharmaceutical services such as drug delivery technologies, or those involved in the broader logistics and distribution network necessary for bringing these products to market. By investing in these enablers, the fund supports the infrastructure necessary for the successful development, manufacturing, and distribution of GLP-1 agonist medications.
